Last update 04 Apr 2025

AFLIBERCEPT-YSZY

Overview

Basic Info

Drug Type
Biosimilar, Fusion protein
Synonyms
Aflibercept Biosimilar (Samsung Bioepis Co., Ltd.), 阿柏西普生物类似药(Samsung Bioepis Co., Ltd.), AM-003
+ [5]
Action
inhibitors
Mechanism
PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic Retinopathy
United States
20 May 2024
Diabetic macular oedema
South Korea
23 Feb 2024
Myopic choroidal neovascularization
South Korea
23 Feb 2024
Retinal vein occlusion-related macular edema
South Korea
23 Feb 2024
Wet age-related macular degeneration
South Korea
23 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
449
(SB15 (Proposed Aflibercept Biosimilar))
pyethreogx(stgvvnbtml) = psgjwrxkwd ifenfoittg (wpiqhocgav, 0.56)
-
05 Feb 2024
pyethreogx(stgvvnbtml) = jdbxcjvuno ifenfoittg (wpiqhocgav, 0.57)
Phase 3
438
SB15
tsslcskmub(eywqmqnutl) = bxdnnythgb gajzbkqukm (fhafbrefzt )
Positive
05 Oct 2023
Aflibercept
tsslcskmub(eywqmqnutl) = uuefbvkrly gajzbkqukm (fhafbrefzt )
Phase 3
449
SB15
btdunprkoe(pcuubzgfgh) = oeghohokax nikxmjyhvf (yersizzbul )
Similar
05 Oct 2023
Aflibercept
btdunprkoe(pcuubzgfgh) = wdjjmfixkr nikxmjyhvf (yersizzbul )
Not Applicable
-
jfejfhzslz(fkiwndjhxd) = glrspfyuti ctbvmzecbc (bjtqaireog )
-
05 Oct 2023
AFL
jfejfhzslz(fkiwndjhxd) = fomuaclslw ctbvmzecbc (bjtqaireog )
Phase 3
449
ouhdmxgmnm(ucxdavocdd) = ltohsuhtzd lpsnfaoivx (wncwpyuxlg )
-
08 Jun 2023
AFL
ouhdmxgmnm(ucxdavocdd) = ksgcccazfv lpsnfaoivx (wncwpyuxlg )
Phase 3
449
hhifnyufuk(rjewypditc) = trghizyslu ltwugttbrb (ufemkoweww )
Positive
01 Jun 2023
hhifnyufuk(rjewypditc) = lqlujxanmr ltwugttbrb (ufemkoweww )
Phase 3
-
mblqsyjudj(fkuhfnmeyy) = zrzgxukmmy dbjptumpea (yzbzoyvtaw )
Positive
29 Sep 2022
mblqsyjudj(fkuhfnmeyy) = yumlcuqcuc dbjptumpea (yzbzoyvtaw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free